Persistent Bone Marrow Minimal Residual Disease is a Poor Prognostic Marker for Neuroblastoma

被引：0
|
作者：
Feng, C. [1 ]
Li, Y. [1 ]
Wu, P. [1 ]
Xiong, X. [1 ]
Peng, X. [1 ]
Weng, W. [1 ]
机构：
[1] Sun Yat Sen Mem Hosp, Pediat Hematol Oncol, Guangzhou, Guangdong, Peoples R China
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO130 SIOP
引用
收藏
页码：S605 / S606
页数：2
相关论文
共 50 条
  • [1] Minimal Residual Disease is a Prognostic Marker for Neuroblastoma With Bone Marrow Infiltration
    Cai, Jiao-Yang
    Pan, Ci
    Tang, Yan-Jing
    Chen, Jing
    Ye, Qi-Dong
    Zhou, Min
    Xue, Huiliang
    Tang, Jing-Yan
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (03): : 275 - 278
  • [2] Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for high-risk neuroblastoma
    Reynolds, CP
    Seeger, RC
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2001, 23 (03) : 150 - 152
  • [3] Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma
    Horibe, K
    Fukuda, M
    Miyajima, Y
    Matsumoto, K
    Kondo, M
    Inaba, J
    Miyashita, Y
    MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 36 (01): : 203 - 204
  • [4] MOLECULAR MARKERS APPLICATION FOR BONE MARROW MINIMAL RESIDUAL DISEASE DETECTION IN NEUROBLASTOMA PATIENTS
    Druy, Alexander
    Tsaur, Grigory
    Popov, Alexander
    Shorikov, Egor
    Saveliev, Leonid
    Fechina, Larisa
    PEDIATRIC BLOOD & CANCER, 2010, 55 (05) : 888 - 889
  • [5] Circulating Tumor Cells As a Surrogate Marker for Bone Marrow Minimal Residual Disease and an Adverse Prognostic Factor for Patients with Multiple Myelom
    Huhn, Stefanie
    Hanel, Mathias
    Hielscher, Thomas
    Bertsch, Uta
    Salwender, Hans Jurgen
    Peter, Norma
    Kirchner, Hartmut
    Bernhard, Helga
    Vogel, Martin
    Angermund, Ralf
    Goerner, Martin
    Weisel, Katja C.
    Duering, Jan
    Blau, Igor W.
    Weinhold, Niels
    Goldschmidt, Hartmut
    BLOOD, 2017, 130
  • [6] Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma
    Mohan, Meera
    Szabo, Aniko
    Yarlagadda, Naveen
    Gundarlapalli, Sravani
    Thanendrarajan, Sharmilan
    Kendrick, Samantha
    Schinke, Carolina
    Alapat, Daisy
    Sawyer, Jeffrey
    Tian, Erming
    Tricot, Guido
    van Rhee, Frits
    Zangari, Maurizio
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (09) : E341 - E344
  • [7] Disease burden-dependent correlation of neuroblastoma minimal residual disease between bone marrow and peripheral blood
    Kyawsan, Lin
    Uemura, Suguru
    Thwin, Khinkyaemon
    Ishida, Toshiaki
    Yamamoto, Nobuyuki
    Nishimura, Noriyuki
    CANCER SCIENCE, 2022, 113 : 1498 - 1498
  • [8] From normal bone marrow to minimal residual disease
    Bene, M. Ch.
    Arnoulet, Ch.
    Durrieu, F.
    Feuillard, J.
    Fossat, Ch.
    Husson, B.
    Jouault, H.
    Maynadie, M.
    Lacombe, F.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2008, 74B (01) : 50 - 51
  • [9] Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: A pilot study
    Fukuda, M
    Miyajima, Y
    Miyashita, Y
    Horibe, K
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2001, 23 (01) : 10 - 13
  • [10] Prognostic impact and detection of minimal residual disease (MRD) in neuroblastoma patients
    Druy, Alexander
    Tsaur, Grigory
    Popov, Alexander
    Verzhbitskaya, Tatiana
    Shorikov, Egor
    Saveliev, Leonid
    Fechina, Larisa
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345